More Perfect Cure Rates for Achillion's Six-Week Hep C Treatment

September 28, 2015

Achillion has released new data showing excellent results from six weeks of treatment with the company's investigational hepatitis C virus (HCV) therapy odalasvir (ACH-3102) and Gilead Sciences' Sovaldi (sofosbuvir). Achillion conducted a Phase II, open-label, randomized, partial-crossover study of six or eight weeks of the NS5A inhibitor odalasvir and Sovaldi among treatment-naive people with genotype 1 of hep C.

The study initially enrolled 18 participants. At first, 12 of them were given eight weeks of treatment while six others went untreated (the observation group). Of the treated individuals, 10 had genotype 1a and the other two had genotype 1b. All 12 achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure). The treatment proved well tolerated, with the participants experiencing no significant adverse side effects.

The researchers then enrolled six new participants, who, along with the six from the observational group, were treated with odalavir and Sovaldi for six weeks. Half of the group had genotype 1a and the other half genotype 1b. All of these particpants were cured as well.

Another group of six participants, of whom five had genotype 1a and one had genotype 1b, were also given six weeks of treatment. All were cured.

To read a press release about the study, click here.

© 2026 Smart + Strong All Rights Reserved.

http://beta.docker.hepmag.com/article/six-week-odalasvir-27846-1875807745